How a Medical Writing Partnership Drives Regulatory Success

Navigating regulatory approvals demands precision, expertise, and collaboration. Our long-standing partnership with a global biopharmaceutical leader has driven success across multiple therapeutic areas, accelerating submissions and ensuring timely approvals worldwide.

Innovative Authoring Approaches

• Collaborate with sponsor teams to extensively pre-plan key messages, fostering stakeholder buy-in and ensuring cross-document consistency
• Adopt practices of lean authoring and strategic review to streamline document development
• Work with statistical programming teams to accelerate creation of in-text data displays

Document Authoring Across Clinical Development Lifecycle

• Clinical Study Protocols (CSPs)
• Investigator’s Brochures
• Clinical Study Reports (CSRs)
• Paediatric Investigation Plans / Pediatric Study Plans
• Agency Briefing Documents

Multi-Market Regulatory Submission Development

• Common Technical Document (CTD)
• Clinical Summaries and Overviews
• Integrated Summaries of Efficacy, Safety, & Immunogenicity
• Risk Management Plans (RMPs)
• Responses to Health Authority Queries
• Post-marketing Updates

Expert Medical Writing Leadership

• Project management for large-scale regulatory submissions
• Quality control & compliance with regulatory standards
• Cross-functional collaboration with product teams

Why Our Expertise Matters

Regulatory & Compliance Mastery
Seamless integration into regulatory workflows

Cross-functional Collaboration
Active engagement with industry-leading teams

Technical System Expertise
Facility with Electronic Document Management Systems and collaborative authoring tools. Ability to quickly learn and adapt to new technologies and processes

Strategic Messaging & Clarity
Production of cohesive, high-impact regulatory documentation

• 2013 – Initiated Medical Writing support under a master services agreement.
• 2016 – Approval for a treatment for chronic respiratory disease.
• 2017 – Approval secured for a biologic therapy in a severe respiratory condition.
• 2019 – Authorization granted for a biologic therapy self-administration option.
• 2019 – Expanded collaboration to support vaccine submissions.
• 2020 – Approval achieved for a treatment for chronic respiratory disease.
• 2021 – Regulatory approval for an emergency vaccination program.
• 2023 – Adopted an accelerated regulatory submission document authoring model.
• 2024 – Approval obtained for a treatment targeting rare inflammatory disease.
• 2024–2025 – Continued contributions to global marketing applications and document authoring strategies.

With a proven track record in regulatory medical writing, our expertise accelerates the approval of groundbreaking therapies, bringing innovative treatments to patients faster.